Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Gains from Sales and Divestitures (2023 - 2024)

Historic Gains from Sales and Divestitures for Ocular Therapeutix (OCUL) over the last 4 years, with Q4 2025 value amounting to $1.6 million.

  • Ocular Therapeutix's Gains from Sales and Divestitures rose 2147.4% to $1.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6 million, marking a year-over-year increase of 2147.4%. This contributed to the annual value of $1.6 million for FY2025, which is 2147.4% up from last year.
  • As of Q4 2025, Ocular Therapeutix's Gains from Sales and Divestitures stood at $1.6 million, which was up 2147.4% from $1.3 million recorded in Q4 2024.
  • In the past 5 years, Ocular Therapeutix's Gains from Sales and Divestitures ranged from a high of $1.6 million in Q4 2025 and a low of $393805.0 during Q4 2023
  • In the last 3 years, Ocular Therapeutix's Gains from Sales and Divestitures had a median value of $1.3 million in 2024 and averaged $1.1 million.
  • Per our database at Business Quant, Ocular Therapeutix's Gains from Sales and Divestitures skyrocketed by 22437.32% in 2024 and then soared by 2147.4% in 2025.
  • Over the past 3 years, Ocular Therapeutix's Gains from Sales and Divestitures (Quarter) stood at $393805.0 in 2023, then surged by 224.37% to $1.3 million in 2024, then grew by 21.47% to $1.6 million in 2025.
  • Its Gains from Sales and Divestitures stands at $1.6 million for Q4 2025, versus $1.3 million for Q4 2024 and $393805.0 for Q4 2023.